DAMORA THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
DAMORA THERAPEUTICS, INC. (DMRA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $68.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $5.00K, a 66.67% increase year-over-year.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $63.00K, a 2000.00% increase year-over-year.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.00K.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $5.00K, a 90.74% decline year-over-year.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $12.00K, a 92.50% decline from fiscal 2024.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $160.00K, a 71.48% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $561.00K, a 25.22% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $448.00K, a 6.41% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $68.00K 10-Q · filed 2026-08-10 | $69.00K derived: sum of 3 quarters · filed 2026-08-10 | $74.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $63.00K 10-Q · filed 2026-05-12 | $64.00K derived: sum of 2 quarters · filed 2026-05-12 | $69.00K derived: sum of 3 quarters · filed 2026-05-12 | $72.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.00K derived: sum of 2 quarters · filed 2026-03-19 | $9.00K derived: sum of 3 quarters · filed 2026-08-10 | $12.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.00K derived: sum of 2 quarters · filed 2026-08-10 | $11.00K 10-Q · filed 2025-11-06 | -$48.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $6.00K 10-Q · filed 2026-08-10 | -$53.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $3.00K 10-Q · filed 2026-05-12 | -$56.00K derived: sum of 2 quarters · filed 2026-05-12 | -$2.00K derived: sum of 3 quarters · filed 2026-05-12 | $70.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$5.00K derived: sum of 2 quarters · filed 2026-03-19 | $67.00K derived: sum of 3 quarters · filed 2026-03-19 | $160.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $126.00K derived: sum of 2 quarters · filed 2025-11-06 | $219.00K 10-Q · filed 2025-11-06 | $425.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $165.00K 10-Q · filed 2025-08-05 | $371.00K derived: sum of 3 quarters · filed 2025-08-05 | $527.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $93.00K 10-Q · filed 2025-05-08 | $299.00K derived: sum of 2 quarters · filed 2025-05-08 | $455.00K derived: sum of 3 quarters · filed 2025-05-08 | $533.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $362.00K derived: sum of 2 quarters · filed 2025-03-19 | $440.00K derived: sum of 3 quarters · filed 2025-03-19 | $561.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $234.00K derived: sum of 2 quarters · filed 2024-11-01 | $355.00K 10-Q · filed 2024-11-01 | $498.00K derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $199.00K 10-Q · filed 2024-08-12 | $342.00K derived: sum of 3 quarters · filed 2024-08-12 | $440.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $121.00K 10-Q · filed 2024-04-29 | $264.00K derived: sum of 2 quarters · filed 2024-04-29 | $362.00K derived: sum of 3 quarters · filed 2024-04-29 | $459.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $241.00K derived: sum of 2 quarters · filed 2024-03-08 | $338.00K derived: sum of 3 quarters · filed 2024-03-08 | $448.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $195.00K derived: sum of 2 quarters · filed 2023-11-06 | $305.00K 10-Q · filed 2023-11-06 | $409.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $207.00K 10-Q · filed 2023-07-31 | $311.00K derived: sum of 3 quarters · filed 2023-07-31 | $421.00K derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $110.00K 10-Q · filed 2023-04-28 | $214.00K derived: sum of 2 quarters · filed 2023-04-28 | $324.00K derived: sum of 3 quarters · filed 2023-04-28 | $434.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $214.00K derived: sum of 2 quarters · filed 2023-03-09 | $324.00K derived: sum of 3 quarters · filed 2023-03-09 | $421.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $220.00K derived: sum of 2 quarters · filed 2022-11-08 | $317.00K 10-Q · filed 2022-11-08 | $369.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $207.00K 10-Q · filed 2022-07-29 | $259.00K derived: sum of 3 quarters · filed 2022-07-29 | $341.00K derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | $97.00K 10-Q · filed 2022-04-29 | $149.00K derived: sum of 2 quarters · filed 2022-04-29 | $231.00K derived: sum of 3 quarters · filed 2022-04-29 | $260.00K derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $134.00K derived: sum of 2 quarters · filed 2022-02-17 | $163.00K derived: sum of 3 quarters · filed 2022-02-17 | $188.00K 10-K · filed 2022-02-17 |
| 2020-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $111.00K derived: sum of 2 quarters · filed 2021-11-04 | $136.00K 10-Q · filed 2021-11-04 | $166.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $54.00K 10-Q · filed 2021-08-05 | $84.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $25.00K 10-Q · filed 2021-05-04 | $55.00K derived: sum of 2 quarters · filed 2021-05-04 | ||
| 2019-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $111.00K 10-K · filed 2021-03-29 | ||
| 2019-09-30 | $81.00K 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |